Phase 1 Pharmacokinetic Study Of CP-945598 In Patients With NASH
Status:
Completed
Trial end date:
2008-11-01
Target enrollment:
Participant gender:
Summary
CP-945598 is a potent and selective Cannabinoid-1 (CB1) receptor antagonist currently being
developed for the treatment of obesity. CP-945598 is also being considered as a potential
treatment for non-alcoholic steatohepatitis (NASH). This study will investigate the
steady-state safety, toleration and pharmacokinetics of multiple oral dose administration of
CP-945598. Results will be used to estimate the pharmacokinetic characteristics in NASH
patients and underwrite the safety of this compound prior to any further studies in NASH
patients.